ROYALTY PHARMA PLC- CL A
RPRXNASDAQTrading Snapshot
- Day Range
- $58.36 β $59.35
- 52-Week Range
- $34.08 β $60.44
- Volume
- $3.86B
- Avg Volume
- $4.34B
- Shares Outstanding
- 443.3M
- Next Earnings
- Sep 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.38B
- Last Q Revenue
- $674M
- P/E Ratio
- 24.4
- P/S Ratio
- 10.3x
- EPS (TTM)
- $1.83
- Dividend Yield
- 1.54%
Why Investors Own RPRX
- βHigh-growth profile β revenue up +27.6% YoY with expanding US Equity exposure.
- βHealthy economics β 78% gross margin and 23% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ROYALTY PHARMA PLC- CL A
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Otter Score Breakdown
βAnalyst Ratings
βLatest News & Updates
Dividend Champion, Contender, And Challenger Highlights: Week Of August 9
Weekly dividend activity roundup for Dividend Champions, Contenders & ChallengersΓ’ΒΒsee dividend changes, upcoming ex-dividend dates and pay dates here.
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62
JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $58 to $62.
Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan
Teva Pharmaceutical Industries Limited turnaround: Pivot to Growth, raised 2026 guidance, $3.7B specialty target, and more. Click for this TEVA update.
Royalty Pharma (NASDAQ:RPRX) Beats Q2 Revenue Estimates, Raises Full-Year Guidance
Royalty Pharma Q2 revenue beats, EPS in line, raises FY2026 guidance; shares rise premarket.
Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript
Royalty Pharma plc (RPRX) Q2 2026 Earnings Call August 5, 2026 8:00 AM EDTCompany ParticipantsGeorge Grofik - Senior VP and Head of Investor Relations &...
Royalty Pharma plc 2026 Q2 - Results - Earnings Call Presentation
2026-08-05. The following slide deck was published by Royalty Pharma plc in conjunction with their 2026 Q2 earnings call.